6rpn

Publication Abstract from PubMed

beta-Lactamases comprise the most widely used mode of resistance to beta-lactam antibiotics. Cyclic boronates have shown promise as a new class of beta-lactamase inhibitor, with pioneering potential to potently inhibit both metallo- and serine-beta-lactamases. We report studies concerning a bicyclic boronate ester with a thioether rather than the more typical beta-lactam antibiotic "C-6/C-7" acylamino type side chain, which is present in the penicillin/cephalosporin antibiotics. The thioether bicyclic boronate ester was tested for activity against representative serine- and metallo-beta-lactamases. The results support the broad inhibition potential of bicyclic boronate based inhibitors with different side chains, including against metallo-beta-lactamases from B1, B2, and B3 subclasses. Combined with previous crystallographic studies, analysis of a crystal structure of the thioether inhibitor with the clinically relevant VIM-2 metallo-beta-lactamase implies that further SAR work will expand the already broad scope of beta-lactamase inhibition by bicyclic boronates.

Broad Spectrum beta-Lactamase Inhibition by a Thioether Substituted Bicyclic Boronate.,Parkova A, Lucic A, Krajnc A, Brem J, Calvopina K, Langley GW, McDonough MA, Trapencieris P, Schofield CJ ACS Infect Dis. 2020 Jan 6. doi: 10.1021/acsinfecdis.9b00330. PMID:31841636^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.